Phase 2 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to sign a written consent form
- People who have been confirmed, through a tissue or cell sample, to have cancer of the colon or rectum (adenocarcinoma)
- People whose tumor has been tested and found to have a specific genetic feature known as mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H)
- People aged 18 to 75 years, either male or female
- People with a general health and activity level rated as 0 or 1 on a standard medical scale (meaning fully active or restricted in strenuous activity but able to carry out light work)
- People who have had a CT or MRI scan of the chest, abdomen, and pelvis within the past 14 days showing locally advanced disease (confirm with trial site for exact staging details)
- People whose tumor is not currently causing a blockage, rupture, or bleeding
- People who have not previously received any cancer treatment for their colorectal cancer
- People with adequate blood, liver, and kidney function based on blood tests done within 7 days of starting the study treatment
Who may not be able to join:
- People who have had or currently have a different cancer (other than colorectal cancer) within the past 5 years
- People who have had a serious heart condition, such as unstable chest pain or a heart attack, within the past 6 months
- People with severe heart failure (Grade III or IV on a standard medical scale)
- People who still have significant side effects remaining from a previous treatment or medical procedure
- People with a known allergy to the study drugs or any of their ingredients
- People who have taken part in another clinical trial or received an experimental drug within the past 4 weeks
- People who are pregnant or breastfeeding
- People for whom effective contraception is not in place
- People who have previously received certain types of immunotherapy drugs that work on immune system checkpoint pathways (including PD-1, PD-L1, or CTLA-4 targeted treatments)
- People whose cancer has spread to distant parts of the body (metastatic disease)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yanhong Deng, M.D., Sixth Affiliated Hospital, Sun Yat-sen University
Phone: 86-13925106525
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Pathological complete response (pCR) rates (PICC-1 and PICC-2 cohorts); Event-free survival (EFS) (PICC-3 cohort)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.